• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Modified Herpes Virus Shows Promise for Treating Advanced Melanoma

Modified Herpes Virus Shows Promise for Treating Advanced Melanoma

Rendering of combination pembrolizumab (green form at top center) and T-VEC (green circles with red centers) in action. Image: Courtesy of UCLA Jonsson Comprehensive Cancer Center

In a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers found that the side effects of the treatment were manageable and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.

UCLA scientists are testing the combination of pembrolizumab and T-VEC as a treatment option for people with advanced melanoma who do not fully respond to either treatment separately. T-VEC is a genetically modified version of the herpes simplex virus that causes cold sores but is safe to use. T-VEC already has been approved for the treatment of melanoma, and it works both by directly killing cancer cells and using a protein that attracts immune cells into the cancers.

Pembrolizumab has become a standard-of-care treatment for advanced melanoma, and it also is being used to treat non-small-cell lung cancer; cancers of the head, neck, kidney and bladder; and Hodgkin's disease. It works by taking the “brakes” off the body's immune system, enabling it to attack cancer.

Antoni Ribas, MD, professor of molecular and medical pharmacology and director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, says people whose melanoma does not respond to pembrolizumab often lack a type of T cell called CD8+ in their tumors; the lack of CD8+ cells seems to prevent immunotherapy drugs from working. But the researchers believe those people might benefit from a combination therapy because T-VEC attracts CD8+ immune cells to the tumors, and pembrolizumab allows them to attack the cancer cells.

The phase 1 clinical trial evaluated 21 people with advanced melanoma. Researchers injected patients' melanoma tumors with T-VEC for six weeks and then gave them infusions of pembrolizumab. Sixty-two percent of the patients had a partial or complete response, meaning that their tumors either shrank or were no longer detectable. The combination therapy could provide an alternative treatment for people with melanoma whose tumors don't respond to other therapies. It also is being tested in people with head, neck and colon cancers.

“Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy,” Cell, September 7, 2017


Previous
As Re-hospitalizations Go Down, Mortality Goes Up
Next
Weak Burst of Electricity Can Help to Improve Memory


YOU ARE VIEWING

Winter 2018

Winter 2018
Printable PDF
IN THIS ISSUE
  • Partners in Care
  • Mobile Stroke Unit: Hospital on Wheels
  • Sip Black Tea to Drop Pounds
  • As Re-hospitalizations Go Down, Mortality Goes Up
  • Modified Herpes Virus Shows Promise for Treating Advanced Melanoma
  • Weak Burst of Electricity Can Help to Improve Memory
  • Heart's Pumping Function Doesn't Indicate Heart Failure Survival Rates
  • Biomarkers Could Reveal Undetected Concussions
  • Researchers Create Molecule that Could 'Kick and Kill' HIV
  • Study Blames Mental Lapses on Sleep-deprived Brain Cells
  • Behavioral Therapy Increases Connectivity in Brains of People with OCD
  • New Direction in Hand Transplantation
  • UCLA Vine Street Clinic
  • Tailor Made
  • Ilana and the Stowaway
  • Heartfelt
  • Awards/Honors
  • In Memoriam
  • Department of Surgery Celebrates Inaugural Paul I. Terasaki Chair in Surgery
  • Out of Africa, Into Iraq
  • Rides, Games and Laughter on the Pier
  • UCLA Health System Board Meeting Features Stroke Care
  • UCLA Launches New Mobile Stroke Unit
  • UCLA Operation Mend Marks a 10-year Milestone
  • Celebrating 60 Years of Excellence in Cardiovascular Research
  • The Spectacular Sounds of Autism
  • Family’s Bravery Leads to Generosity
  • A Legacy for Loved Ones
  • Gifts
  • In Memoriam
  • ‘I Have Been on Both Sides’
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth